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18-Dec-06 10:13 PM progeny cells. 6 Longer telomere length of cord blood cells has been proposed as a poss explanation for the greater proliferative capacity of cord blood. 7 The immunologic properties of cord blood differ from mature bone marrow or peripheral stem cells. The initial clinical observations of decreased graft-versus-host disease (GVH following related cord blood transplantation prompted investigation into the unique immun features of cord blood cells. 8, 9 Cord blood contains a high proportion of T cells expressin CD45RA + /CD45RO -, CD62L + "naive" phenotype. 10 The chemokine receptor CCR5, exp by T helper 1 T cells, is less abundant among cord blood compared with adult T cells.
studies show that cord blood cells produce increased amounts of the anti-inflammatory c interleukin-10, which may downmodulate graft-versus-host disease. 12 Cord blood banking The American Red Cross Cord Blood Program, North Central region, investigated a pha consent policy. 16 The phased consent approach is a 3-step process involving (1) targetin information about cord blood banking to pregnant women; (2) allowing early labor ex utero collection and temporary storage of cord blood; and (3) permitting postcollection to the permanent storage, donation, and testing of the cord blood. Mothers who were elig intralabor consent had to meet strict eligibility criteria including dilation less than 7 cm, than 18 years, more than 36 weeks gestation, and no use of narcotics.
A purported goal of the cord blood banks is to increase minority donation, to help serve t patients who have a more difficult time finding donors through the National Marrow Dono 18-Dec-06 10:13 PM Program (NMDP) and other international registries. However, an early study of 5 differen blood banks found no improvement in cord blood donation from minorities compared with marrow registries in the same geographic area. 17 In fact, in California, Florida, and Massachusetts, the cord blood banks recruited a lower percentage of minorities than the corresponding marrow donor centers. A more recent survey of the American Red Cross blood banks revealed a diverse donor population: 64% white, 16% African American, 12%
Hispanic, 4% Asian, 1% Native American, and 3% other. 18 Nucleated cell counts were s among the different racial/ethnic groups, but CD34 + counts were lower for blacks in the M Northwest, and North Carolina collection sites. These data suggest that even greater rec efforts are needed to increase the number of suitable cord blood units from certain racial groups. The current racial/ethnic composition of the NMDP cord blood registry is 52% wh African American, 5% Asian, 13% Hispanic, 12% multiple race, 1% Native American, and other or unknown (personal written communication, NMDP, 2004). Thus, increased recen attention to minority recruitment has resulted in more diverse cord blood units.
Collection of the cord blood unit
The cord blood can be collected either in utero, before the delivery of the placenta, or ex after placental delivery. In utero collections are usually performed by the obstetrician midwife attending the delivery, while trained personnel from the cord blood bank, who pe collection outside the delivery room, more often perform ex utero collections. The St Lou
Blood Bank uses an obstetrician-based cord blood collection network, using more than 2 delivering physicians and 40 obstetric units. 19 In contrast, the 3 cord blood banks National Heart, Lung, and Blood Institute Cord Blood Transplantation Study (COBLT) use technicians who collected the cord blood following the delivery of the placenta. 20 utero collections are less invasive, and there is better control over technique, but they ma more expensive because of the additional personnel involved. One study showed counts and CD34 + counts with either method. 21 The New York Blood Center harvests th blood from the delivered placenta and has reported an association between length of the cord and volume of collection. 22 There have been no reports of a serious adverse event either in utero or ex utero collections.
Processing and freezing of the cord blood unit
Most of the cord blood banks operate under strict guidelines, analogous to blood banks, instituted by either NETCORD, FACT (Foundation for Accreditation of Cellular Therapy), AABB (American Association of Blood Banks). 23 For example, the group in Milan operat a strict quality control system, which controls staff organization and training, procedures, collection and storage, and periodic audits. 24 In the early years (1993) (1994) (1995) (1996) of cord bloo banking, the cord blood was frozen as whole blood in 10% dimethylsulphoxide (DMSO).
considerations became paramount, and the cord blood volume was reduced by removal blood cells and plasma. 25 Freezing is usually done at a controlled rate, such as 1°C a m down to -4°C, then transferred to -80°C freezer, and finally to either the liquid or vapor ph liquid nitrogen freezers, achieving a temperature of less than -180°C, for long-term storag
Recovery of hematopoietic progenitor cells (colony-forming unit-granulocyte macrophag [CFU-GMs]) has been studied in cord blood cells frozen for up to 12 years. Recovery wa than 90% at 10 years. 27 Blood from the maternal donor is tested for infectious disease markers, including tests fo 18-Dec-06 10:13 PM syphilis, human T-cell lymphotropic virus 1 (HTLV-1), HIV, hepatitis B, and hepatitis C. R nucleic acid testing has been used as a more sensitive test for hepatitis B and HIV infect addition, blood is tested for cytomegalovirus (CMV) antibodies. The cord blood unit itself cultured, and HLA testing, usually by molecular methods, is used. A nucleated cell count and after processing, CD34 + testing, and in some cases, CFU-GMs are tested on the product. The lack of standardization among banks for CD34 and CFU-GM testing makes comparison of cord blood units difficult. About half of the cord blood units collected and for banking are not frozen for potential transplant use; the most common reason is a low product. In Italy, the mother and baby are re-evaluated at 6 months after delivery, medical history and repeat infectious disease tests are obtained. This program has a 95% success rate of having the mothers return at 6 months; based on this 6-month checkup, (0.3%) were discarded. 28 The procedure in American banks varies from no maternal foll distribution of contact materials to the mother in case of the baby's illness, postpartum ph calls, to a formal 6-month visit.
Release of cord blood unit to transplant center
Possible HLA-matched cord blood units for patients are found via computerized registrie NMDP has approximately 34 000 units listed from several cord blood banks; transplant coordinators can locate cord blood units for patients via the NMDP computerized while also performing an unrelated bone marrow donor search. The New York Blood Cen example, has its own search engine, and transplant centers can contact the bank for potential units. In Europe, the NETCORD system has 59 000 listed units. Rubinstein pioneered a popular thawing technique, using a dextran/albumin wash. 13 The technique different from a standard bedside thaw and requires an experienced laboratory.
Congress has recently allocated federal funds in support of cord blood banking and transplantation. 29 The Institute of Medicine has been asked for advice on the appropriate funds.
One advantage of cord blood as opposed to unrelated bone marrow is the speed of the s process, since there is no living donor to contact and retest. 30 Clinical studies in cord blood transplantation
Pediatric studies
Related donor transplantations. Although the primary interest in cord blood is as an alt unrelated donor source, umbilical cord blood has been used successfully in related trans both malignant and nonmalignant diseases. 9 The Eurocord group reported on 102 childr acute leukemia receiving cord blood transplants; 42 received a related donor transplant.
these patients, 12 received a mismatched graft; neutrophil engraftment was 84% and 2-y event-free survival was 41%. A nucleated cell dose more than 3.7 x 10 7 /kg correlated wi engraftment. The same group recently analyzed their results for related cord blood transp children with sickle cell anemia and thalassemia. 32 There were 44 patients who received cord blood transplant. The 100-day transplant-related mortality was 0; 4 patients experie grade 2 acute GVHD. Of the patients, 1 with sickle cell disease and 7 with thalassemia have sustained donor engraftment. The 2-year probability of event-free survival was 79% thalassemia and 90% for sickle cell anemia. Cord blood, a naturally T-cell-depleted prod a low risk of graft-versus-host disease, and may be well suited to the treatment of nonma 18-Dec-06 10:13 PM diseases, where there is no need for a graft-versus-leukemia effect.
Unrelated cord blood transplantations. The first unrelated cord blood transplantations performed in children. The first 25 unrelated cord blood transplantations were reported in Of these patients, 24 were children, and 30% were nonwhite and had searched for an un marrow donor for at least 6 months. The cord blood was mismatched to the patient at 1 t loci. Of 55 patients, 23 engrafted. There were 2 patients with graft-versus-host disease, a event-free survival was 48% with a median follow-up of 12 months. These data suggeste engraftment could occur even with cord blood units that were mismatched at 2 loci, that severe graft-versus host-disease was low, and that a higher cell dose may be an importa prognostic feature.
This work has been followed by several studies, showing similar results in children. The N Blood Center reported on 562 cases, 82% children, who underwent transplantation in a v centers with differing conditioning regimens and graft-versus-host disease prophylaxis.
Engraftment was 81%, and the risk of grades III to IV GVHD was 23%. Younger age and nucleated cell dose/kg infused correlated with improved engraftment and survival. Result improved with selection of cord blood units with higher cell doses. The Eurocord group a 95 children receiving unrelated cord blood transplants for acute myeloid leukemia.
nucleated cell dose per kilogram was 5.2 x 10 7 . Transplant-related mortality was 20%; 2 disease-free survival was 42% for patients in complete remission 1 (CR1), 50% for patie CR2, and 21% for refractory patients.
Wagner et al 36 from the University of Minnesota performed transplantations in 102 childr unrelated umbilical cord blood. Of the children, 65 had malignant diseases (68% high ris 37 had nonmalignant diseases. The incidence of neutrophil engraftment was 88%, and p engraftment 65%. The incidence of graft-versus-host disease was low; severe acute GV seen in 11% of patients and chronic GVHD, in 10% of patients. The low incidence of graft-versus-host disease following cord blood transplantations has raised the question o a detrimental decrease in the graft-versus-leukemia effect occurs. In this study, the rate leukemia relapse was low, 17% for standard-risk patients and 45% for high-risk patients.
transplant-related mortality was 30% and survival at 2 years was 47%.
There have been no randomized studies comparing outcomes after unrelated bone marr unrelated cord blood transplantation. However, there have been retrospective matched p analyses. Rocha et al compared 113 related cord blood recipients with 2052 related bone recipients. 37 GVHD was lower among cord blood patients, and mortality was similar betw 2 groups, which included patients with both malignant and nonmalignant diseases. The E group also compared children receiving unrelated 1-to 2-antigen-mismatched cord bloo transplants, unrelated matched and 1-antigen-mismatched bone marrow transplants, an unrelated T-cell-depleted bone marrow transplants. 38 Engraftment was delayed in the co group, and acute GVHD was decreased in the cord blood and T-cell-depleted groups. Th disease-free survival was comparable, 31% for cord blood, 37% for the T-cell-depleted g and 43% for the unrelated marrow group.
Cord blood transplantation has also been shown effective in metabolic storage diseases.
were 20 children with Hurler syndrome who received conditioning with busulfan, cyclophosphamide, and antithymocyte globulin followed by infusion of unrelated 1-, 2-, or 3-antigen-mismatched cord blood. 39 With a median follow-up of 905 days, 17 of 20 child 18-Dec-06 10:13 PM alive with complete donor chimerism and normal peripheral blood alpha-1-iduronidase
The results from some of the major pediatric, nonregistry studies are outlined in Table 1 general, the pediatric data indicate that cord blood transplantation can be successful, eve patient and cord blood donor are mismatched at 2 antigens. 40 Therefore, the potential do is considerably increased from unrelated bone marrow or peripheral blood stem cells. 
Adult unrelated cord blood transplantation
Some of the initial studies of cord blood transplantation included adult patients, but the m patients were children. 33, 34 In the last 5 years, several investigators have published the cord blood transplantations in adult patients. These studies have included patients with le lymphoma, and myelodysplasia, treated with a variety of conditioning regimens and GVH prophylaxis regimens. Laughlin et al 41 analyzed the outcome of 68 adults, median age 3 who received cord blood transplants. Of the patients, 71% received units that were mism 2 or more HLA antigens. The incidence of neutrophil engraftment was 90%, but the med to engraftment was delayed compared with unrelated bone marrow, at 27 days. The med to a platelet count more than 20 x 10 9 /L unsupported was 58 days. Grade III or IV acute was seen in 20% of patients, and chronic GVHD in 30% of the evaluable patients.
Transplant-related mortality was high in this series; 47% of patients died prior to day +10 infection was the leading cause of death, followed by regimen-related toxicity. Of the pati Slightly better results have been reported from the Spanish and Japanese groups. There patients, median age 29 years, who received cord blood transplants. 43 Median days to n and platelet engraftment were 22 and 69, respectively. Disease-free survival was 53% at year. Younger age was correlated with improved survival. The Japanese group reported for 18 patients with acute myelogenous leukemia receiving cord blood transplants.
regimen was cyclophosphamide, cytosine arabinoside, and total body irradiation. The me cryopreserved cell dose was 2.5 x 10 7 nucleated cells/kg. The median time to neutrophil engraftment was 23 days. Acute GVHD grades II to IV were seen in 11 patients. The 2-y probability of disease-free survival was 76%. An additional study from this group compar 18-Dec-06 10:13 PM outcomes among 8 acute leukemia patients receiving umbilical cord blood to outcomes o patients receiving unrelated bone marrow. 45 Patients received the same conditioning reg GVHD prophylaxis, and supportive care regimen. Hematopoietic recovery was delayed in blood group, chronic GVHD was higher in the cord blood group, and acute GVHD was comparable. The probability of 2-year disease-free survival was similar between this small study, 85% for cord blood versus 75% for bone marrow.
Recently, the International Bone Marrow Transplant Registry reported results of a study comparing survival after unrelated umbilical cord blood transplantations to survival after u bone marrow transplantations. 46 A total of 116 adults with leukemia receiving unrelated, 2-antigen-mismatched cord blood transplants were compared with 367 adults receiving unrelated donor bone marrow transplants and 83 patients receiving 1-antigen-mismatch marrow transplants. The median cell dose was 2.2 x 10 7 nucleated cells/kg, slightly lowe the Japanese study. Deaths related to infection were highest in the cord blood recipients acute GVHD was less likely in the cord blood group, compared with the mismatched bon cohort. The 3-year leukemia-free survival was 33% for HLA-matched bone marrow, 23%
blood, and 19% for 1-antigen-mismatched bone marrow. These results suggest that out are improved for patients receiving a matched unrelated bone marrow transplant;
cord blood and 1-antigen-mismatched unrelated bone marrow had similar survival rates.
At the same time, the Eurocord group reported results of a retrospective study comparing outcomes of 98 adults with acute leukemia receiving unrelated 1-or 2-antigen-mismatch blood with 584 adults with acute leukemia receiving unrelated matched bone marrow transplants. 47 Neutrophil recovery was delayed after cord blood transplantation (26 days days). Graft failure occurred in 20% of the cord blood recipients and 7% of the bone recipients. The incidence of grades II to IV acute GVHD was 26% after cord blood transp and 39% after unrelated bone marrow transplantation. Relapse was similar in both group 2-year leukemia-free survival was similar in both groups, 33% for cord blood and 38% fo unrelated bone marrow. This study suggests that outcomes after cord blood transplantat be similar to outcomes after matched unrelated bone marrow transplantation.
The Japanese group has just published impressive data comparing 68 adult unrelated co recipients with 45 adult unrelated bone marrow recipients. Ninety-four percent received a dose of more than 2.0 x 10 7 nucleated cells/kg. Neutrophil and platelet engraftment were in the cord blood recipients. The transplant-related mortality was 9% for cord blood recip 29% for unrelated bone marrow recipients. The 2-year probability of disease-free surviva 74% for cord blood and 44% for unrelated bone marrow. 48 These results are superior to reported in the American and European series, perhaps due to the smaller size and gene homogeneity of this population.
The results of the single cord blood studies in adults are presented in Table 2 . These stu show that engraftment can be achieved in adult patients but is delayed compared with un bone marrow. Early transplant-related mortality is high, mostly due to infection 
Sequential cord blood transplantation
Pooled or sequential cord blood transplantation is the addition of a second, partially matc blood unit to increase the cell count and improve engraftment and immune reconstitution report of patients infused with multiple, mismatched units suggested that crossed immun rejection would not occur. 49 The University of Minnesota program has done extensive double or sequential cord blood transplantation, using a nonmyeloablative regimen, and published impressive results. Barker et al 50 transplanted 1 or 2 cord blood units to achie minimum cell dose of 3.5 x 10 7 nucleated cells/kg. Of the patients, 21 received condition busulfan/fludarabine/low-dose TBI, and 22 received cyclophosphamide/fludarabine/low-d
Cyclosporine and mycophenolate mofetil were used for GVHD prophylaxis. Of the 43 pat received 2 cord blood units. The incidence of neutrophil engraftment was 76% for the firs regimen and 94% for the second regimen; the median days to an absolute neutrophil mm 3 were 26 for the first regimen and 10 for the second regimen. The risk of grades III o acute GVHD was 9%. The 100-day transplant-related mortality was 48% for the busulfan regimen and 28% for the cyclophosphamide-based regimen. Overall survival at one year 39%. These studies have shown that in ablative transplantations the incidence of increased, but the time to engraftment was not changed; also, for patients receiving a nonmyeloablative regimen, the day +10 myeloid recovery was autologous, and engraftm cord units occurred later after transplantation.
We have pursued the sequential cord blood transplant approach in a current phase 1 stu 
Cord blood expansion
There have been many preclinical trials studying expansion of cord blood cells using a va cytokine mixtures. 51, 52 One approach is to use a continuous perfusion device. In the study using the Aastrom/Replicell system, 28 patients received a conventional single cor transplant, followed by the infusion of the expanded cells on day +12 after transplantatio ex vivo-expanded cells were well tolerated, but engraftment was unchanged. The 3-year probability of event-free survival was 39%.
Shpall et al 54 expanded a portion (40%-60%) of the cord blood unit using a combination cell factor, granulocyte colony-stimulating factor (G-CSF), and megakaryocyte growth an Combination cord blood and haploidentical bone marrow transplant
The Spanish group has pioneered this unique approach. There were 11 adults who rece single cord blood units and haploidentical CD34 + selected cells from a family member.
Neutrophil engraftment occurred at 12 days (range, 9-36 days). There were 4 patients experienced grade II or higher acute GVHD. Of the 11 patients, 5 survive disease free w complete cord blood chimerism at 6 to 43 months after transplantation.
There are now alternatives to single cord blood transplantation for adult patients. The seq cord blood results appear promising in terms of neutrophil recovery, and a low risk of more work is needed in larger studies with diverse patient populations. A suggested algo choosing an optimal donor source for adults is presented in Figure 1 . Patients who matched sibling donor should search simultaneously for unrelated bone marrow and unre cord blood. Patients without time to find an unrelated bone marrow donor, or who a 10/10 or 9/10 unrelated adult volunteer donor should be considered for cord blood transplantation. The goal should be to procure a safe donor source, either bone marrow blood, in a timely fashion so no appropriate patients are denied transplantation.
Unique problems in cord blood transplantation
Early infections continue to be a major problem in allogeneic transplantation. Because of delayed immune reconstitution, infections are a serious problem in cord blood transplant
The Spanish group analyzed the infections in 27 adult patients undergoing cord blood transplantation. 56 In this group of patients, 55% experienced bacteremia, 58% develope infection, and 11% had documented fungal disease. In this study, there were 3 deaths re Acinetobacter infection. Recommendations for management include prophylaxis against bacterial, and pneumocystis infections; frequent monitoring of CMV antigenemia; replacement of gamma globulin for immunoglobulin G levels below 500 mg/dL. An additi problem unique to cord blood transplantation is that the original donor cannot be reconta donor lymphocyte infusion or more cells. Back-up donor sources should be reviewed prio blood transplantation. Some of the unique issues related to cord blood transplantation ar in Table 3 . 
Future trends in cord blood transplantation
As we look ahead to the next 5 to 10 years in cord blood transplantation, there will be con studies on adult cord blood transplantation, with more centers examining double cord blo transplantation. Future trials are needed to define the best application of cord blood trans the transplant donor choice algorithm. There might be a future indication for cord blood in a matched unrelated donor, for example, in elderly patients with a high risk of graft-versu disease. The unique immunologic properties of cord blood likely contribute to a decrease graft-versus-host disease. Additional experience in nonmalignant diseases is also One application could be autoimmune diseases, where there has been some success wi autologous transplantation and the low risk of graft-versus-host disease makes cord bloo transplantation attractive. 57 Another intriguing application is in HIV disease, a major worl public health problem, in which the possibility of gene transfer to a hematopoietic reservoir may eventually be possible. 58 In theory, an allogeneic stem cell vaccine may re hematopoietic stem cells infected with HIV with uninfected umbilical cord blood cells.
Potential exciting uses of cord blood may be nonhematopoietic applications, such as the damaged myocardium or neural tissue. Cord blood cells are a more primitive population adult bone marrow, and have increased capacity for multilineage differentiation. 58 blood cells have been shown to improve functional recovery in rats who have been subje strokes, by middle cerebral artery occlusion. 59 Infarct volume was reduced and behavior performance increased when a higher dose of cord blood cells was infused.
Summary
Over the last 10 years, we have seen the growth in use of a common, often discarded ste Reprints: Karen K. Ballen, Massachusetts General Hospital, 100 Blossom St, Cox 640, MA 02114; e-mail: kballen@partners.org.
